Status:
UNKNOWN
Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
People's Hospital of Chongqing
Hong Kong University of Science and Technology
Conditions:
Atherosclerosis, Coronary
Eligibility:
All Genders
30-60 years
Phase:
PHASE4
Brief Summary
Background: Longterm exposure to air pollution has been associated with cardiovascular events and mortality on top of traditional risk factors. Pulmonary inflammation and oxidative stress have been im...
Detailed Description
2\. Introduction Atherosclerosis related complications, in particular stroke and coronary artery disease, are the most important health issues in modernized societies, being the leading cause of death...
Eligibility Criteria
Inclusion
- asymptomatic Chinese adults
- aged 30-60 years with
- concordant ambient PM2.5 exposure, both at home and at workplace.
Exclusion
- Those with family history of stroke, cardio-vascular disease
- Hypertension with blood pressure \>150/90 mmHg
- Diabetics Mellitus
- Overweight/ obesity (BMI \>25kg/M2)
- Cigarette smoking or ex-smoker \<5 years
- Known dyslipidemia defined as fasting LDL-C \>4.1mmol/l and triglyceride \>3.0 mmol/l.
- Physical inactivity, with weekly leisure exercise less than 0.5 hour
- Continuous usage of vitamins or herbal medicines in recent one year
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04762472
Start Date
September 1 2023
End Date
December 30 2025
Last Update
February 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong, Department of Medicine & Therapeutics
Shatin, Hong Kong